Polarean shares rise 7% on expanded FDA approval for lung imaging agent

Polarean Imaging (POLX) shares rose 7% after the FDA expanded approval for its XENOVIEW lung imaging agent to include children as young as six, down from the previous age threshold of 12. This approval potentially opens access to an additional one million patients with chronic respiratory conditions and enhances the technology's appeal to hospitals. Polarean plans a targeted launch of a paediatric system later this year, beginning with Cincinnati Children’s Hospital.

Analysis

Polarean Imaging PLC has received a significant regulatory milestone with the U.S. Food and Drug Administration's approval to expand the use of its XENOVIEW lung imaging agent to children aged six and older, a notable decrease from the previous minimum age of 12. This decision is anticipated to unlock a considerable market expansion, potentially providing access to an additional one million paediatric patients with chronic respiratory conditions. XENOVIEW, which facilitates the measurement of lung ventilation in MRI scans without exposing patients to radiation, will now be complemented by new paediatric-specific dose delivery bags and updated equipment, a move designed to improve the technology's appeal and utility within hospital settings. Polarean plans a targeted rollout of this paediatric system commencing later this year, with Cincinnati Children’s Hospital being an initial site. The market registered a positive response to this news, evidenced by a 7% rise in Polarean's shares to 1.36p.

Key Decisions for Investors

• Investors should recognize this expanded FDA approval as a material positive development that significantly increases XENOVIEW's addressable market and strengthens Polarean's commercial prospects in the paediatric respiratory diagnostics sector.
• It is advisable to monitor the progress of the targeted launch, particularly initial adoption rates at key institutions like Cincinnati Children’s Hospital, as these will be early indicators of the technology's traction within the newly approved age group.
• Consider the potential for enhanced revenue streams and market penetration resulting from this approval, while also evaluating the company's execution capabilities in scaling up for this expanded paediatric application.